---
name: medlog-OTel SEC/SRE/FIN panel per-point on Deep×2 r13
description: 2026-05-15 — ~43rd stacked-COI case; SEC/SRE/FIN panel per-point on Deep×2 r13 medlog-OTel; 0 CHALLENGE bidirectional, 4 panel-unique adds (parallel stabilise+extract-14, audit-SLO-before-shadow, per-phase budget gates, historic §164.400 breach-notification question), $55-115K to decision; saturation reframed as the finding
type: project
originSessionId: b1633175-4bdd-4937-b800-430d2afaaac4
---
2026-05-15 medlog-OTel SEC/SRE/FIN panel per-point on Deep×2 r13 (~43rd stacked-COI case across 9 domains).

**Bidirectional CHALLENGE count: 0.**

**Panel-unique adds (not in any Deep r1–r13):**
- SEC: stabilise + extract-14 should run in parallel, not sequentially — extract-14 doesn't touch prod
- SEC: historic 14 incidents may carry unresolved §164.400–414 breach-notification questions independent of migration
- SEC: prefer compliance-counsel + external-HIPAA-auditor seats over external-CTO for next round
- SRE: audit-completion SLO + error budget must precede shadow run, otherwise diff arguments are unbounded
- SRE: also recuse Daniel from authoring the shadow-run diff harness, not just equivalence sign-off
- FIN: per-phase budget envelope ($30–60K stabilise+extract / $5–15K external review / $20–40K shadow) → ~$55–115K to *decision*; migration capex still gated
- FIN: cost of round-14 internal review ≥ cost of one external HIPAA-counsel review that would actually move the question

**Verdict alignment with Deep×2:** sequenced stabilise → extract-14 → external HIPAA review → shadow → conditional hybrid migrate; recuse Daniel from equivalence sign-off; recuse self from review chain. Stable.

**Meta:** saturation across 13 passes reframed as the *finding* — review trail without remediation is materially worse than not having reviewed under §164.308(a)(1)(ii)(A). Next productive action is external (compliance counsel / HIPAA auditor / non-conflicted SRE), not another internal round.
